miR‑342 inhibits glioma cell proliferation by targeting GPRC5A

Wang,Jianjiao; Yang,Yan; Cao,Yuandong; Tang,Xinyu

doi:10.3892/mmr.2019.10242

miR‑342 inhibits glioma cell proliferation by targeting GPRC5A

Authors:
- Jianjiao Wang
- Yan Yang
- Yuandong Cao
- Xinyu Tang
View Affiliations

Affiliations: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: May 15, 2019 https://doi.org/10.3892/mmr.2019.10242
Pages: 252-260
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence suggests that microRNAs (miRNAs) play a key role in the biological behaviors and progression of glioma. However, the function and bio‑molecular mechanisms of miR‑342 in glioma remain largely unclear. In the present study, reverse transcription quantitative‑polymerase chain reaction and western blotting were performed to determine the mRNA and protein expression levels of the factors investigated. MTT assay was performed to examine the proliferation rates. Luciferase reporter assay was performed to test the binding between miRNA‑342 and its putative target. Data indicated that miR‑342 expression was markedly decreased in human glioma tissues and cell line U87, and reduced miR‑342 expression significantly promoted cell proliferation. In order to explore the mechanisms, G‑protein coupled receptor family C group 5 member A (GPRC5A) was identified as a target of miR‑342 and depletion of GPRC5A suppressed cell proliferation. Our findings demonstrated that miR‑342 regulates the cell proliferation of glioma by targeting GPRC5A, which indicates that miR‑342 is a target of interest regarding the treatment of refractory glioma, and it may provide a promising prognostic and therapeutic strategy for glioma treatment.

View Figures

View References

1	Gu X, Gong H, Shen L and Gu Q: MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A. Am J Transl Res. 10:2834–2847. 2018.PubMed/NCBI
2	Ji ZG, Jiang HT and Zhang PS: FOXK1 promotes cell growth through activating wnt/β-catenin pathway and emerges as a novel target of miR-137 in glioma. Am J Transl Res. 10:1784–1792. 2018.PubMed/NCBI
3	Gao Y, Lin L, Li T, Yang J and Wei Y: The role of miRNA-223 in cancer: Function, diagnosis and therapy. Gene. 616:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
4	Wang F, Liang S, Liu X, Han L, Wang J and Du Q: LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer. Onco Targets Ther. 11:6383–6394. 2018. View Article : Google Scholar : PubMed/NCBI
5	Liu W, Kang L, Han J, Wang Y, Shen C, Yan Z, Tai Y and Zhao C: miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. Onco Targets Ther. 11:1643–1653. 2018. View Article : Google Scholar : PubMed/NCBI
6	Xue X, Fei X, Hou W, Zhang Y, Liu L and Hu R: miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer Lett. 412:170–178. 2018. View Article : Google Scholar : PubMed/NCBI
7	Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF and Babu MM: Molecular signatures of G-protein-coupled receptors. Nature. 494:185–194. 2013. View Article : Google Scholar : PubMed/NCBI
8	Solinski HJ, Gudermann T and Breit A: Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol Rev. 66:570–597. 2014. View Article : Google Scholar : PubMed/NCBI
9	Jin E, Wang W, Fang M, Wang W, Xie R, Zhou H, Ye J, Xu R and Ma S: Clinical significance of reduced GPRC5A expression in surgically resected non-small cell lung cancer. Oncol Lett. 17:502–507. 2019.PubMed/NCBI
10	Gu C, Zhou N, Wang Z, Li G, Kou Y, Yu S, Feng Y, Chen L, Yang J and Tian F: circGprc5a promoted bladder oncogenesis and metastasis through Gprc5a-targeting peptide. Mol Ther Nucleic Acids. 13:633–641. 2018. View Article : Google Scholar : PubMed/NCBI
11	Klaschik K, Hauke J, Neidhardt G, Tränkle C, Surowy HM, Heilmann-Heimbach S, Rappl G, Mangold E, Arnold N, Niederacher D, et al: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. Int J Cancer. 144:1761–1763. 2019. View Article : Google Scholar : PubMed/NCBI
12	Jing L, Li H, Zhang T, Lu J and Zhong L: MicroRNA-4530 suppresses cell proliferation and induces apoptosis by targeting RASA1 in human umbilical vein endothelial cells. Mol Med Rep. 19:3393–3402. 2019.PubMed/NCBI
13	Zhu Y, Zhao H, Rao M and Xu S: MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3. Oncol Rep. 37:2185–2192. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang H, Tang C, Na M, Ma W, Jiang Z, Gu Y, Ma G, Ge H, Shen H and Lin Z: miR-422a inhibits glioma proliferation and invasion by targeting IGF1 and IGF1R. Oncol Res. 25:187–194. 2017. View Article : Google Scholar : PubMed/NCBI
15	Zhi T, Jiang K, Xu X, Yu T, Wu W, Nie E, Zhou X, Jin X, Zhang J, Wang Y and Liu N: MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1. Am J Transl Res. 9:4872–4887. 2017.PubMed/NCBI
16	Gu G, Wang L, Zhang J, Wang H, Tan T and Zhang G: MicroRNA-384 inhibits proliferation migration and invasion of glioma by targeting at CDC42. Onco Targets Ther. 11:4075–4085. 2018. View Article : Google Scholar : PubMed/NCBI
17	Ma J, Yu J, Liu J, Yang X, Lou M, Liu J, Feng F, Ji P and Wang L: MicroRNA-302a targets GAB2 to suppress cell proliferation, migration and invasion of glioma. Oncol Rep. 37:1159–1167. 2017. View Article : Google Scholar : PubMed/NCBI
18	Romero-Cordoba SL, Rodriguez-Cuevas S, Bautista-Pina V, Maffuz-Aziz A, D'Ippolito E, Cosentino G, Baroni S, Iorio MV and Hidalgo-Miranda A: Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer. Sci Rep. 8:122522018. View Article : Google Scholar : PubMed/NCBI
19	Hu K, Mu X, Kolibaba H, Yin Q, Liu C, Liang X and Lu J: Metadherin is an apoptotic modulator in prostate cancer through miR-342-3p regulation. Saudi J Biol Sci. 25:975–981. 2018. View Article : Google Scholar : PubMed/NCBI
20	Zhu X, Li W, Zhang R and Liu Y: MicroRNA-342 inhibits cell proliferation and invasion in nasopharyngeal carcinoma by directly targeting ZEB1. Oncol Lett. 16:1298–1304. 2018.PubMed/NCBI
21	Gentry PR, Sexton PM and Christopoulos A: Novel allosteric modulators of G protein-coupled receptors. J Biol Chem. 290:19478–19488. 2015. View Article : Google Scholar : PubMed/NCBI
22	Scholz N, Gehring J, Guan C, Ljaschenko D, Fischer R, Lakshmanan V, Kittel RJ and Langenhan T: The adhesion GPCR latrophilin/CIRL shapes mechanosensation. Cell Rep. 11:866–874. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP and Guitart X: G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev. 66:413–434. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kumari P, Ghosh E and Shukla AK: Emerging approaches to GPCR ligand screening for drug discovery. Trends Mol Med. 21:687–701. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS and Lotan R: A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia. 12:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
26	Liu S, Ye D, Wang T, Guo W, Song H, Liao Y, Xu D, Zhu H, Zhang Z and Deng J: Repression of GPRC5A is associated with activated STAT3, which contributes to tumor progression of head and neck squamous cell carcinoma. Cancer Cell Int. 17:342017. View Article : Google Scholar : PubMed/NCBI
27	Zhou H and Rigoutsos I: The emerging roles of GPRC5A in diseases. Oncoscience. 1:765–776. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhou H and Rigoutsos I: MiR-103a-3p targets the 5′UTR of GPRC5A in pancreatic cells. RNA. 20:1431–1439. 2014. View Article : Google Scholar : PubMed/NCBI